financetom
Business
financetom
/
Business
/
Ex-RBI Guv Subbarao says depositors must oppose interest waiver on loans during moratorium
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Ex-RBI Guv Subbarao says depositors must oppose interest waiver on loans during moratorium
Jun 4, 2020 1:12 PM

It is not possible for banks to waive interest accrued on loans during the moratorium period, D Subbarao, former RBI Governor said in an interview to CNBC-TV18.

Echoing Uday Kotak's views earlier in the day, Subbarao said that banks had contractual obligations to both savers and borrowers.

"If banks waive that sort of interest, there will be enormous strain on them," Subbarao said.

"They earn interest from borrowers and they have got to service the deposits. If the borrowers are not to pay interest, how are the banks to service the savers? Banks are supposed to be hard-headed, whether they are hard-hearted or not is not the question.

So banks cannot be expected to privilege one side over here. They have got contractual obligations both to savers and to borrowers and you have got to balance both of them, they cannot privilege the interest of the borrowers or the interest of the savers."

He said that depositors associations must raise the concerns of savers.

“There is in fact an All India Depositors Association, I think they must jump in and argue the interest of the depositors across the country. We think of small borrowers, MSMEs etc but on the savers side as well we have very small people, people saving a few thousand rupees and you cannot expect them to support the waiver of loans to borrowers," he said.

So I think the All India Depositors Association or whatever other association there is must come into the picture and argue the case of depositors because I believe hearing out their case is very important to get a well-received judgement on this issue.”

Speaking on RBI's role in the matter, Subbarao said: “RBI is the banking regulator. Waiving of interest is a commercial decision. I do not think RBI's regulatory authority extends to overseeing a commercial decision by the bank.

Waiving of interest is a commercial decision which the banks have to take, I don’t believe the RBI can mandate the banks to do that.

If in fact that happens and the present financial stability is threatened then RBI can in fact be charged with not fulfilling its regulatory mandate of preserving financial stability. So I think the stand RBI has taken is very correct.”

First Published:Jun 4, 2020 10:12 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform
Zai Lab Licenses MediLink Therapeutics' Antibody-Drug Conjugate Platform
Jan 10, 2025
04:39 AM EST, 01/10/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said late Thursday it has struck a licensing agreement to use MediLink Therapeutics' Tmalin antibody-drug conjugate platform for the development of its ZL-6201 investigational drug. Financial terms were not disclosed. Zai Lab ( ZLAB ) said the partnership will expand its oncology pipeline with another drug targeting multiple...
Amylyx Pharmaceuticals Launches Stock Offering
Amylyx Pharmaceuticals Launches Stock Offering
Jan 10, 2025
04:31 AM EST, 01/10/2025 (MT Newswires) -- Amylyx Pharmaceuticals ( AMLX ) said late Thursday it has commenced an underwritten public offering of common shares. Amylyx plans to give the underwriter a 30-day option to buy up to an additional 15% of the shares offered. The company said the proceeds will be used to support commercialization, pipeline programs, working capital...
Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth
Innate Pharma to Focus on NK Cell Therapies, ADC Development to Accelerate Growth
Jan 10, 2025
04:39 AM EST, 01/10/2025 (MT Newswires) -- Innate Pharma ( IPHA ) said Friday it is prioritizing its antibody-based NK Cell Engager platform to target hematologic cancers, solid tumors, and autoimmune diseases. The company said it is currently testing its NK Cell Engager, IPH6501, in a phase 1/2 trial for non-Hodgkin's lymphoma. Additionally, Innate said it is advancing its Antibody-Drug...
Thermo Fisher Scientific Says Olink Platform Chosen by UK Proteomics Project
Thermo Fisher Scientific Says Olink Platform Chosen by UK Proteomics Project
Jan 10, 2025
04:21 AM EST, 01/10/2025 (MT Newswires) -- Thermo Fisher Scientific ( TMO ) said late Thursday the UK Biobank Pharma Proteomics Project has chosen its Olink Explore Platform to support a human proteomics study. Financial terms were not disclosed. The project will analyze more than 5,400 proteins from 600,000 samples to help find new biomarkers that could potentially identify, diagnose...
Copyright 2023-2026 - www.financetom.com All Rights Reserved